Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Products
Citizenship »
« Back
Careers
Insights
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Products
Citizenship »
« Back
Careers
Insights
Investors »
« Back

Aclaris - Investor Relations

Investor overview
Stock information
Press releases
Events
SEC filings
Corporate governance
Investor presentations
Investor FAQs
Email alerts

Investor contact

For investor related questions, please email

investors@aclaristx.com

Media contact
& resources »

Press Releases

Press Releases

Year

January 9, 2020

Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor

January 8, 2020

Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors

Aclaris - Footer Menu

Terms of use
Privacy policy
Media resources
Contact us

© 2020 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.